Johnson & Johnson (JNJ)
Johnson & Johnson (JNJ) is currently trading at $241.00, demonstrating strong upward momentum. The company operates within the Healthcare sector, specifically in Drug Manufacturers - General, a resilient industry. Recent revenue growth of 9.9% indicates healthy top-line expansion. The P/E ratio stands at 26.81, with an EPS of $8.63, suggesting a valuation that reflects its stable market position and growth prospects. Despite a significant net seller verdict from insider transactions, the overall fundamental and technical picture remains positive, positioning JNJ as a core holding for investors seeking stability and growth.
The company's substantial market capitalization of over $580 billion underscores its position as a healthcare giant. While insider selling warrants attention, it is crucial to consider the broader context of JNJ's diversified business segments and ongoing innovation pipeline. The dividend yield of 2.17% offers an additional income stream, making it attractive for income-focused investors. JNJ's ability to consistently deliver on revenue growth and maintain profitability in a dynamic healthcare landscape supports its current valuation and outlook.
Price Analysis
Market Metrics
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
JNJ Analysis
Johnson & Johnson's technical indicators signal strong bullish momentum. The stock is trading above its 50-day ($230.24) and 200-day ($216.61) SMAs, as well as its 20-day EMA ($233.65), indicating an established uptrend. The RSI at 70.1, while in overbought territory, suggests sustained buying pressure. The MACD at 1.94 and CCI at 118.19 further reinforce the bullish sentiment, pointing to strong price appreciation.
Key support levels are now established around the moving averages, particularly the 50-day SMA. Resistance is not clearly defined by the current technicals, suggesting potential for further upside. The stochastic oscillator at 88.10 also indicates strong momentum, though it too is in overbought territory, hinting at a possible short-term consolidation. Overall, the chart structure is constructive, favoring further gains in the near term.
- Monitor insider selling activity closely; a continued trend could signal underlying concerns despite positive technicals.
- Given the RSI is in overbought territory, consider scaling into positions or employing a tighter stop-loss strategy.
- The dividend yield of 2.17% provides a defensive income component, making JNJ a potentially resilient holding during market volatility.
Johnson & Johnson reported a 9.9% revenue growth, indicating robust demand for its products and effective market strategies, which supports continued stock appreciation.
Source: Company DataThe stock is trading above key moving averages (50-day, 200-day SMA, 20-day EMA) with bullish MACD and CCI readings, suggesting sustained upward price action.
Source: Technical AnalysisInsiders have executed a heavy insider selling with $129M in sales versus $257.7K in purchases, indicating a lack of confidence from management and posing a risk to future stock performance.
Source: Insider TransactionsThe RSI is at 70.06, signaling overbought conditions which historically can precede a short-term pullback or consolidation phase.
Source: Technical AnalysisJohnson & Johnson is poised for continued stability and moderate growth over the next 6-12 months, driven by its strong position in the healthcare sector and consistent revenue generation. The current technical setup, with the stock trading above key moving averages and showing bullish momentum, suggests that the upward trend is likely to persist. A target price around $265.10, reflecting a modest upside from the current price and aligning with analyst targets, is achievable if the company continues to execute on its growth strategies and navigate regulatory environments effectively.
The primary upside catalysts would involve continued strong performance from its pharmaceutical division, successful new drug approvals, and positive clinical trial results. Conversely, significant downside risks include intensified competition from pharmaceutical peers like Pfizer (PFE) and AbbVie (ABBV), adverse regulatory changes impacting drug pricing, or a more pronounced sell-off driven by the insider selling trend. Any unexpected negative clinical trial outcomes or major product recalls could also derail the positive outlook.
Key Statistics
| Market Cap | 580.14B |
| P/E Ratio | 26.80 |
| EPS (TTM) | 8.63 |
| Dividend Yield | 2.17% |
| 52 Week High | 251.71 |
| 52 Week Low | 150.73 |
Johnson & Johnson's valuation, with a P/E ratio of 26.81 and EPS of $8.63, aligns with its position as a leading player in the stable healthcare sector. While not inexpensive, its P/E is comparable to industry peers like Eli Lilly (LLY) and Merck (MRK), which also trade at premium multiples due to their strong R&D pipelines and market dominance. The revenue growth of 9.9% is robust for a company of its size, indicating effective market penetration and product demand. The company's ability to generate consistent earnings supports its current valuation.
The balance sheet strength is implied by its market leadership and consistent performance, though specific debt-to-equity and ROE figures are not provided in this data snapshot. However, its consistent revenue growth and profitability suggest efficient operations. The dividend yield of 2.17% further enhances its fundamental appeal, providing a steady return to shareholders. JNJ's diversified business model across pharmaceuticals, medical devices, and consumer health provides resilience against sector-specific downturns.
Earnings & Growth Analysis
Johnson & Johnson's reported revenue growth of 9.9% highlights its strong performance in the latest period. While specific EPS figures for the most recent quarter are not detailed, the trailing twelve months EPS of $8.63 indicates solid profitability. The company's consistent ability to grow its top line suggests effective product launches and market strategies within the competitive healthcare landscape. Investors should look towards future earnings reports for confirmation of sustained growth and potential upward revisions in forward guidance.
Key Risks
The primary risk for Johnson & Johnson stems from the significant insider selling activity, with a net seller verdict and a heavy sell signal, indicating potential concerns among management regarding future stock performance. Additionally, the stock's RSI is in overbought territory (70.06), suggesting a potential for a short-term pullback or consolidation. Competitive pressures within the pharmaceutical and medical device sectors, along with evolving regulatory landscapes, also pose ongoing risks.
Technical Indicators
| RSI (14) | 70.06 |
| MACD | 1.94 |
| SMA 50 | 230.24 |
| SMA 200 | 216.61 |
Actionable Trade Plans
Specific entry, exit, and risk management levels
Entry Strategies (click to switch)
Risk Management
Profit Targets (Based on Conservative Entry)
Growth of $10,000
Compare with Another Ticker
Monte Carlo Projection (10yr)
People Also Watch
Insider Trading Analysis
Source: SEC Form 4| Date | Insider | Type | Shares | Value |
|---|